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ABSTRACT
Introduction: Metabolic syndrome (MetS) is a group of cardiovascular risk factors characterized by the
presence of low-grade chronic inflammation. Among all the inflammatory biomarkers associated with
MetS, the best characterized and well standardized is C-Reactive protein (CRP). Objectives: To evaluate the
association between C-Reactive protein and metabolic syndrome in the Peruvian population of the PERU
MIGRANT study. Methods: Secondary database analysis of the PERU MIGRANT study. MetS was considered
according to the Harmonizing the Metabolic Syndrome criteria. For CRP, a cutoff point of ≥ 3 mg/L was
established. Results: We worked with a total of 958 subjects. The prevalence of MetS was 24.53%. In the
simple regression analysis, it was found that people with high CRP levels had a 75% higher frequency of
having MetS, compared to those who did not present high CRP levels (PR = 2.21, 95% CI: 1.40 - 2.18). In
multiple regression, it was observed that patients with high CRP levels had a 31% greater frequency of having
MetS, compared to those with normal CRP levels; adjusting for the rest of the covariates (PR = 1.31, 95% CI:
1.05 - 1.62). Conclusions: Plasma CRP was positively associated with MetS. This suggests that a low-grade
inflammatory process may be related to the presence of MetS. Against this, physicians should pay attention
to glucose, lipid profile, and central obesity in patients with elevated plasma CRP levels.
Key words: Metabolic Syndrome; C-Reactive Protein; Inflammation Mediators (source: MeSH NLM).

RESUMEN
Introducción: El síndrome metabólico (MetS) es un grupo de factores de riesgo cardiovascular que
se caracteriza por la presencia de inflamación crónica de bajo grado. Entre todos los biomarcadores
inflamatorios asociados al MetS, el mejor caracterizado y bien estandarizado es la proteína C-Reactiva
(PCR). Objetivo: Evaluar la asociación entre la proteína C-Reactiva y el síndrome metabólico en la población
peruana del estudio PERU MIGRANT. Métodos: Estudio transversal analítico. Análisis de base de datos
secundario del estudio PERU MIGRANT. Se consideró MetS según los criterios de Harmonizing the Metabolic
Syndrome. Para la PCR, se dispuso un punto de corte ≥ 3 mg/L. Se usó modelos lineales generalizados de
familia de Poisson para hallar la razón de prevalencias cruda y ajustada. Resultados: Se trabajó con un
total de 958 sujetos. La prevalencia de MetS fue de 24,53%. En el análisis de regresión simple, se encontró
que las personas con niveles altos de PCR tenían 75% mayor frecuencia de tener MetS, en comparación
a quienes no presentaban niveles altos de PCR (RP=2,21, IC95%: 1,40 – 2,18). En la regresión múltiple, se
observó que los pacientes con niveles altos de PCR tenían 31% mayor frecuencia de tener MetS, respecto a
quienes presentaban niveles normales de PCR; ajustando por el resto de covariables (RP=1,31, IC95%: 1,05
– 1,62). Conclusiones: La PCR plasmática se asoció positivamente con MetS. Ello sugiere que un proceso
inflamatorio de bajo grado puede estar relacionado con la presencia de MetS.
Palabras clave: Síndrome metabólico; Proteína C-Reactiva; Mediadores de Inflamación (fuente: DeCS
BIREME).
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INTRODUCTION

cardiovascular risk factors(15).

Metabolic syndrome (MetS) is a group of cardiovascular
risk factors characterized by abdominal obesity,
hypertension, and dyslipidemia(1). The prevalence of
metabolic syndrome has increased throughout the
world and has become a major public health problem
recently(2). Almost half of the American adults have
MetS, and the prevalence increases with age(3). In the
case of the Peruvian population, according to the
criteria used, the prevalence fluctuates between 25
and 45%(4).

Population and sample

CRP is an acute phase reactant produced by
hepatocytes, and its production is regulated by
interleukin-6 and other inflammatory cytokines(9,10).
Classically, plasma PCR is used as a test for the
detection and activity of inflammatory diseases, such
as rheumatological diseases(11). However, plasma CRP
levels have also been shown to reflect the course of
certain chronic diseases, including MetS(12–14). Given
these observations found, some investigators have
suggested that CRP should be added as a clinical
criterion for MetS.
Although several countries have studied the
relationship between plasma CRP and metabolic
syndrome, it has not been thoroughly investigated in
the Peruvian population. For this reason, the present
study aims to evaluate the association of C-reactive
protein in metabolic syndrome in the Peruvian
population of the PERU MIGRANT study.

METHODS
Design and study area
The present study had a cross-sectional analytical
observational design. It was a secondary database
analysis of the PERU MIGRANT study. This research
work was designed to evaluate the magnitude of
the differences between rural groups, rural to urban
migrants, and urban ones in relation to specific
https://inicib.urp.edu.pe/rfmh/vol21/iss1/14

Ayacucho was chosen for this study because it was
one of the most affected areas during the conflict
period in Peru, resulting in 50% of the deaths. For
the period 1988-1993, 50.7% of the total emigrants
from Ayacucho moved to Lima, making Ayacucho
the main source of emigrants to Lima.
Additional information on the selection criteria,
sample size, and participation rates have been
published elsewhere. (fifteen).
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Although the individual components of MetS
contribute
independently
to
the
further
development of cardiovascular diseases (CVD) and
type 2 diabetes mellitus (DM2), overall, the risk
increases exponentially(5,6). The precise mechanisms
for this greater propensity lie in the presence of
low-grade chronic inflammation(7,8). Among all the
inflammatory biomarkers associated with evaluating
their value in the prediction of CVD, the best
characterized and well standardized is C-Reactive
protein (CRP).

The PERU MIGRANT study (primary study)
considered two different settings. The first was San
José de Secce, a village located in Ayacucho, which
was selected as the rural study site. The second was
the area "Las Pampas de San Juan de Miraflores" in
Lima, selected as the urban area for the study. Study
groups were defined by a single random sampling of
participants aged 30 years or older from the rural site
of Ayacucho, the urban site of Lima, and migrants
from the countryside to the city of Ayacucho who
now reside in Lima.

Of the total number of participants recruited in
the primary study, 989 people were evaluated. In
the present study, all subjects with the variables
of interest were included, and all subjects with a
diagnosis of DM2 were excluded. Finally, there were
a total of 958 subjects.
With a sample size of 958 subjects, with an expected
proportion of subjects with high MetS and CRP
of 44.5%; and an expected proportion of subjects
with MetS without high CRP of 55.5; and with a
confidence level of 95%, a statistical power of 92.6%
was calculated.

Variables and instruments
The dependent variable was the MetS diagnosis.
MetS was considered according to the Harmonizing
the Metabolic Syndrome criteria(16), presenting
three or more of the following alterations: Waist
circumference ≥ 80 cm for women or ≥ 94 cm for
men; triglycerides ≥ 150 mg / dl; fasting glucose ≥
100 mg / dl (or if they receive treatment to lower
glucose levels); systolic blood pressure ≥ 130 mmHg
or diastolic blood pressure ≥ 85 mmHg (or receive
treatment to lower blood pressure levels); HDLcholesterol <50 mg / dl in women or <40 mg / dl in
men.
Our main exposure variable was plasma ultrasensitive
CRP levels. In this study, a cut-off point was
Pág. 119
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established where CRP was considered high ≥ 3 mg
/ L. The American Heart Association and the Center
for Disease Control recognized that people with CRP
above this value are a high-risk group for CVD(17–19).
The other variables of the analysis were age, gender
(male or female), group according to migration
(urban, rural or migrant), smoker status, alcohol
drinker and physical activity. Excessive alcohol
consumption was defined as low or high alcohol
consumption. Smoking was defined in three
categories: if you have not smoked (never), have
stopped smoking 6 months ago (old) or if you have
smoked in the last 6 months (current). Physical
activity levels were defined according to the
International Physical Activity Questionnaire (IPAQ)
protocol. The categorical physical levels were coded
based on the total number of days of physical activity
and the metabolic equivalent in minutes/week three
categories: high, medium and low.
To collect all the variables of the primary study, a
team of community health workers with previous
experience in fieldwork was trained in-home
visits to enroll the participants and carry out the
questionnaires. All laboratory evaluations were
performed by trained personnel on venous samples
taken in the morning after a minimum of 8 hours of
fasting.

Procedures
The database of the primary study is freely accessible,
without restrictions. The researchers accessed the
scientific information, the variables that were of
interest to the study were taken and the present
manuscript was prepared.

Statistical analysis
Statistical analysis was performed with STATA v16.0
software. For descriptive analysis, the qualitative
variables were summarized in proportions. The
quantitative variables were presented as the mean
and the standard deviation. For the bivariate analysis,
the chi-square test was performed for the categorical
variables, and the Student's T test and Wilcoxon were
chosen for the numerical variables, according to the
normality distribution of the variables.
Subsequently, a generalized linear model of the
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Poisson family (crude and adjusted) with robust
variance was made. The variables included in the
adjusted model were age, gender, group (urban,
rural or migrant), state of smoker, alcohol drinker
and physical activity. The measure of association
was the prevalence ratio (PR) with its respective 95%
confidence interval (CI).

Ethical considerations Ethical
Approval for the primary study was obtained from
the Universidad Peruana CayetanoHeredia’s ethics
committees in Peru and the London School of
Hygiene and Tropical Medicine in the UK. The purpose
of the study was explained to each of the study
participants and informed consent was obtained,
following international standards for ethical research
in developing countries.
This is secondary data analysis, so no contact was
made with human subjects. In this sense, the possible
risks for the subjects of the analysis are minimal.
In turn, it is worth clarifying that the database is freely
accessible to the general public.
Finally, during the study’s implementation, the ethical
principles outlined in the Declaration of Helsinki were
respected.

RESULTS
Of 958 participants selected for this research, the
prevalence of MetS was 24.53%. It was found that
the majority were female (52.92%) and belonged to
the migrant group (59.71%). The mean age was 47.83
years. Almost half practiced high physical activity
(44.84%). 11.17% were current smokers, and 7.31%
reported high alcohol consumption. The fourth part
(25.47%) presented high levels of CRP.
Patients with high CRP levels had a 15.48% higher
frequency of being metabolic syndrome than those
with normal CRP levels (56.60% vs. 25.59%; p <0.001).
It was found that women had an 18.28% greater
frequency of having MetS, compared to men (33.14%
vs. 14.86%; p <0.001). Finally, age was significantly
associated with having MetS (p = 0.005). Only the
smoker state did not show proportional statistical
differences in relation to presenting MetS. Table 1.
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Table 1. Important characteristics of the Peruvian population of the PERU MIGRANT study based on
metabolic syndrome
Metabolic Syndrome
Characteristics

Total

No (n=723)

Yes (n=235)

n (%)

n (%)

n (%)

Gender

p*

< 0.001
Female

507 (52.92)

339 (66.86)

168 (33.14)

Male

451 (47.08)

384 (85.14)

67 (14.86)

Age (years) *

47.83 (± 12.05) 47.20 (± 12,58)

49.76 (± 10.02)

< 0.001
Rural

197 (20.56)

179 (90.86)

18 (9.14)

Migrant

572 (59.71)

421 (73.60)

151 (26.40)

Urban

189 (19.73)

123 (75.47)

66 (34.92)

Low

246 (25.89)

176 (71.54)

70 (28.46)

Moderate

278 (29.26)

195 (70.14)

83 (29.86)

High

426 (44.84)

344 (80.75)

82 (19.25)
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Group

0.005¥

Physical Activity

Smoking status

0.002

0.265
Never

789 (82.36)

594 (75.29)

195 (24.71)

Old

62 (6.47)

43 (69.35)

19 (30.65)

Current

107 (11.17)

86 (80.37)

21 (19.63)

Alcohol consumption

< 0.001
Low

888 (92.36)

662 (74.55)

226 (24.45)

High

70 (7.31)

61 (87.14)

9 (12.86)

High CRP

< 0.001
No

714 (74.53)

567 (79.41)

147 (20.59)

Yes

244 (25.47)

156 (63.93)

88 (36.07)

* Obtained with the Chi square test		
* Mean ± standard deviation.		
¥ Performed with the Student's T test

https://inicib.urp.edu.pe/rfmh/vol21/iss1/14
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In the simple regression analysis, it was found that
people with high levels of CRP had a 75% higher
frequency of having MetS, compared to those who did
not present high levels of CRP (PR = 2.21, 95% CI: 1.402.18). Then, in the multiple regression, the observed
association in terms of direction and magnitude was

Vera V et al

preserved. It was observed that patients with high CRP
levels had a 31% higher frequency of having MetS,
compared to those with normal CRP levels; adjusting
for the confounding covariates of gender, age, group,
smoking status, alcohol drinker and physical activity
(PR = 1.31, 95% CI: 1.05 - 1.62). Table 2.

Table 2. Crude and adjusted Poisson regression model to evaluate the association between plasma
fibrinogen and metabolic syndrome.
Characteristics

Crude
RP

IC 95%

Analysis Adjusted Analysis *
p

RP

95% CI

p

1.05 – 1.62

0.015

ORIGINAL PAPER

high CRP
No

Ref

Yes

1.75

Ref
1.40 – 2.18

< 0.001

1.31

* Adjusted for age, gender, group (urban, rural or migrant), status of smoker, alcohol drinker and physical activity.

DISCUSSION

decreased(24).

Given the long-term implications of MetS on
cardiovascular alterations, and the possible role that
the pro-inflammatory state would play in this process,
the present work aimed to evaluate the association
between CRP and MetS. After performing the analysis
adjusted for the most important covariates, we found
a close relationship between both variables of interest.

The pathophysiological role of CRP in MetS is through
its participation in the process of atherosclerosis,
through several potential mechanisms: 1) CRP can
bind to oxidized LDL; 2) CRP can decrease nitric oxide
production and inhibit angiogenesis; 3) the synergy
between CRP and inflammatory mediators could play
a role in the pathogenesis of atherosclerosis; and 4)
PCR can also activate complement(10,25,26).

Our results indicate that elevated CRP concentrations
are associated with a higher prevalence of MetS. This
result is supported by several epidemiological studies.
The association between MetS and elevated CRP
levels has been demonstrated in non-diabetic CubanAmericans aged ≥30 years(20). A study of 5,728 subjects
showed that subjects with three, four, or five MetS
features were more likely to increase CRP compared
to subjects without any MetS features(21). In Korea,
research concluded that people with normal plasma
CRP levels are less likely to have MetS, as opposed to
those with high levels(22).
In a more recent publication, they found that CRP
screening could identify a larger group of people
who might be at high risk for MetS, regardless of their
weight(23). Finally, one study observed that CRP was
a useful and effective variable in predicting the risk
of developing MetS. The connection of this variable
and the number of criteria for MetS was also clear
because CRP levels increased in the presence of more
MetS factors, and CRP levels in normal individuals
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Several limitations of this study are worth mentioning.
The present analysis was based on a primary study
where a single measurement of the CRP level was
performed without repeating the tests; however, a
first shot already brings us closer to the state of the
subject under study. The population of this study
was only carried out in two cities of the country and
not nationally, so it is possible that this population
does not represent the entire Peruvian population;
however, given the characteristics that they may have
in common, a certain inference could finally be made.

CONCLUSION
Plasma CRP was positively associated with MetS in
the Peruvian population of the PERU MIGRANT study.
The results of this study suggest that a low-grade
inflammatory process may be related to the presence
of MetS. Against this, physicians should pay attention
to glucose, lipid profile, and central obesity in patients
with elevated plasma CRP levels.
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